Nordhealth AS (OSL:NORDH)
Norway
· Delayed Price · Currency is NOK | Market Cap | 1.94B |
| Revenue (ttm) | 601.75M |
| Net Income (ttm) | -150.09M |
| Shares Out | 78.81M |
| EPS (ttm) | -1.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,513 |
| Average Volume | 1,428 |
| Open | 24.40 |
| Previous Close | 24.00 |
| Day's Range | 24.00 - 24.60 |
| 52-Week Range | 23.20 - 40.60 |
| Beta | 0.40 |
| RSI | 40.43 |
| Earnings Date | Apr 10, 2026 |
About Nordhealth AS
Nordhealth AS provides healthcare software solutions in Norway, Finland, Sweden, the United Kingdom, Denmark, Germany, and internationally. Its products include Provet Cloud, a veterinary practice management software (PMS); Diarium, a PMS for therapists that streamlines therapy sessions, booking, and invoicing; Physica, a PMS for physiotherapists; Psykbase, a PMS for psychologists and psychotherapists; EasyPractice, a PMS for therapists; and various PMS for veterinarians under the Vetserve, Sanimalis, Vetvision, and Vetera names. The company’s ... [Read more]
Financial Performance
In 2025, Nordhealth AS's revenue was 50.84 million, an increase of 11.31% compared to the previous year's 45.68 million. Losses were -12.68 million, 65.2% more than in 2024.
Financial numbers in EUR Financial StatementsNews
Nordhealth AS (STU:6E5) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic AI ...
Nordhealth AS (STU:6E5) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic AI Integration
Q4 2025 Nordhealth AS Earnings Call Transcript
Q4 2025 Nordhealth AS Earnings Call Transcript
Nordhealth AS Earnings Call Transcript: Q4 2025
Revenue surpassed EUR 50 million in 2025, with strong recurring growth and low churn. AI strategy and cloud migration are driving operational improvements, while profitability is impacted by ongoing R&D and migration costs. Guidance for 2026 targets continued recurring revenue growth and investment in AI.
Nordhealth AS (FRA:6E5) Q3 2025 Earnings Call Highlights: Revenue Growth and AI Investments ...
Nordhealth AS (FRA:6E5) Q3 2025 Earnings Call Highlights: Revenue Growth and AI Investments Drive Performance
Q3 2025 Nordhealth AS Earnings Call Transcript
Q3 2025 Nordhealth AS Earnings Call Transcript
Nordhealth AS Earnings Call Transcript: Q3 2025
Q3 2025 saw 15.2% revenue growth, driven by strong recurring revenue in core business units and significant R&D investment in AI and DACH localization. Veterinary and Therapy segments posted robust retention and low churn, while guidance for 2025 was reiterated.
Nordhealth AS Earnings Call Transcript: Q2 2025
Revenue and recurring revenue grew strongly in H1 2025, with major enterprise rollouts and AI features set to drive future growth. Investments in DACH localization and AI are accelerating, while profitability is impacted short-term by these initiatives.
Nordhealth AS Earnings Call Transcript: Q1 2025
ARR grew 21.5% year-over-year to EUR 44.9 million, with Q1 2025 revenue up 23% to EUR 12.5 million. Veterinary and therapy segments showed strong retention and cloud migration, while guidance anticipates 12%-17% organic recurring revenue growth for 2025.
Nordhealth AS Earnings Call Transcript: Q4 2024
Q4 2024 saw over 20% organic ARR growth, strong recurring revenue gains, and improved profitability, with Veterinary and Therapy BUs both expanding. 2025 guidance targets 12%-17% organic recurring revenue growth, with a focus on major migrations and new AI product launches.
Nordhealth AS Earnings Call Transcript: Q3 2024
Q3 2024 saw 23.7% organic ARR growth, 26.9% revenue growth, and improved profitability, with strong performance in the veterinary segment and ongoing investments in product development. Recurring revenue growth guidance for 2024 was raised to 18%-23%.
Nordhealth AS Earnings Call Transcript: Q2 2024
Q2 2024 saw 33% revenue growth and early EBITDA less CapEx break-even, driven by strong veterinary cloud performance and disciplined cost management. Recurring revenue guidance of 15%-20% is maintained, with increased investments planned to capture enterprise opportunities and accelerate product migrations.